Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $168.7 million.

  • SAB Biotherapeutics' Cash from Financing Activities rose 25123.21% to $168.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.6 million, marking a year-over-year increase of 154.44%. This contributed to the annual value of -$1.2 million for FY2024, which is 101.76% down from last year.
  • As of Q3 2025, SAB Biotherapeutics' Cash from Financing Activities stood at $168.7 million, which was up 97,134.68% from -$173,844 recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Cash from Financing Activities ranged from a high of $168.7 million in Q3 2025 and a low of -$6.3 million during Q1 2022.
  • Its 3-year average for Cash from Financing Activities is $21.3 million, with a median of -$173,985 in 2025.
  • Per our database at Business Quant, SAB Biotherapeutics' Cash from Financing Activities soared by 37,883.67% in 2021 and then tumbled by 13,794.46% in 2022.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Cash from Financing Activities stood at $36.0 million in 2021, then tumbled by 76.72% to $8.4 million in 2022, then soared by 706.40% to $67.6 million in 2023, then tumbled by 99.68% to $216,961 in 2024, then soared by 25,123.21% to $168.7 million in 2025.
  • Its Cash from Financing Activities was $168.7 million in Q3 2025, compared to -$173,844 in Q2 2025 and -$173,985 in Q1 2025.